Congress subsidizes generic drug makers with no guarantee of lower prices
H.R. 1396 — PILLS Act · Filed by Claudia Tenney (R-NY) · 2 cosponsors · Introduced Feb 14, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
The PILLS Act creates two federal tax credits to incentivize domestic production of generic drugs and biosimilars: a 30–35% production credit on the value added by manufacturers, plus a 25% investment credit for building or upgrading facilities. Both credits phase out after 2030 and exclude companies deemed foreign entities of concern. The credits are transferable and available to eligible taxpayers, including non-profits and tax-exempt entities.
Why we flagged it
The bill's operative mechanism is a direct tax credit (foregone federal revenue) to incentivize domestic generic drug and biosimilar production. While framed as supply-chain security and affordability, it functions as a subsidy to pharmaceutical manufacturers with no binding price controls or public-benefit guarantees.
What the text implies
- Tax credits are transferable to non-manufacturing entities (nonprofits, tax-exempt organizations) under section 6417, potentially allowing financial intermediaries to capture and monetize the subsidy without producing drugs.
- No price-control or affordability requirement: manufacturers receiving credits face no obligation to lower generic drug prices or increase supply to underserved markets; the subsidy may simply improve profit margins.
The full analysis lists 5 implications of this text.
Who stands to gain
Generic drug manufacturers; Biosimilar manufacturers; Pharmaceutical contract manufacturers (CMOs)